system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
Exhibit 10.2 ______________________________________________________________________________ CO-PROMOTION AGREEMENT by and between DOVA PHARMACEUTICALS, INC. and VALEANT PHARMACEUTICALS NORTH AMERICA LLC September 26, 2018 ______________________________________________________________________________ CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 RIGHTS AND OBLIGATIONS 8 2.1 Engagement; Grant of Rights. 8 2.2 Retention of Rights. 9 2.3 Non-Competition; Non-Solicitation. 9 2.4 Dova Trademarks and Copyrights. 10 ARTICLE 3 JOINT STEERING COMMITTEE 11 3.1 Formation of the JSC. 11 3.2 Meetings and Minutes. 11 3.3 Purpose of the JSC. 11 3.4 Decision Making. 13 3.5 Marketing Sub-Committee. 13 ARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14 4.1 Valeant Activities. 14 4.2 Detailing. 15 4.3 Compliance with Applicable Law. 17 4.4 Field Force Personnel Training; Product Materials. 19 4.5 Provisions Related to Field Force Personnel. 21 4.6 Responsibility for Valeant Activity Costs and Expenses. 22 4.7 Data Sharing. 22 ARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23 5.1 Dova Responsibility. 23 5.2 Valeant Involvement. 23 5.3 Inspections. 23 5.4 Pharmacovigilance. 24 5.5 Unsolicited Requests for Medical Information. 24 5.6 Recalls and Market Withdrawals. 25 5.7 Certain Reporting Responsibilities. 25 5.8 Booking of Sales Revenues. 25 5.9 Returns. 25 Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 i CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 TABLE OF CONTENTS (continued) 5.10 Manufacturing; Distribution; Marketing. 25 ARTICLE 6 FINANCIAL PROVISIONS 26 6.1 Promotion Fee. 26 6.2 Milestone Payment. 27 6.3 Reports; Payments. 27 6.4 Taxes. 28 6.5 Determination of Specialty. 29 ARTICLE 7 AUDIT RIGHTS 30 7.1 Recordkeeping. 30 7.2 Valeant Rights. 30 7.3 Dova Rights. 31 ARTICLE 8 INTELLECTUAL PROPERTY 32 8.1 Ownership of Intellectual Property. 32 8.2 Title to Trademarks and Copyrights. 32 8.3 Protection of Trademarks and Copyrights. 32 8.4 Disclosure of Know-How. 33 ARTICLE 9 CONFIDENTIALITY 33 9.1 Confidential Information. 33 9.2 Public Announcements. 34 ARTICLE 10 REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS 35 10.1 Representations and Warranties of Dova. 35 10.2 Representations and Warranties of Valeant. 37 10.3 Disclaimer of Warranty. 38 10.4 Additional Covenants. 39 ARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39 11.1 Indemnification by Dova. 39 11.2 Indemnification by Valeant. 39 11.3 Indemnification Procedures. 40 11.4 Limitation of Liability. 40 11.5 Insurance. 40 ARTICLE 12 TERM AND TERMINATION 41 12.1 Term. 41 12.2 Early Termination for Cause. 41 Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 12.3 Other Early Termination. 42 12.4 Effects of Termination. 42 12.5 Tail Period. 42 ii CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 TABLE OF CONTENTS (continued) 12.6 Survival. 43 ARTICLE 13 MISCELLANEOUS 43 13.1 Force Majeure. 43 13.2 Assignment. 43 13.3 Severability. 44 13.4 Notices. 44 13.5 Governing Law. 45 13.6 Dispute Resolution. 45 13.7 Waiver of Jury Trial. 45 13.8 Entire Agreement; Amendments. 46 13.9 Headings. 46 13.10 Independent Contractors. 46 13.11 Third Party Beneficiaries. 46 13.12 Waiver. 46 13.13 Cumulative Remedies. 46 13.14 Waiver of Rule of Construction. 46 13.15 Use of Names. 46 13.16 Further Actions and Documents. 47 13.17 Certain Conventions. 47 13.18 Counterparts. 47 iii CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 CO-PROMOTION AGREEMENT This Co-Promotion Agreement (this "Agreement") is entered into and dated as of September 26, 2018 (the "Effective Date") by and between Dova Pharmaceuticals, Inc., a Delaware corporation ("Dova"), and Valeant Pharmaceuticals North America LLC, a Delaware limited liability company ("Valeant"). Dova and Valeant are each referred to individually as a "Party" and together as the "Parties". RECITALS WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory; WHEREAS, the Parties believe that it would be mutually beneficial
"""

Extract the exact clause related to "Liquidated Damages" from the excerpt above.